| 0 (0%) | 11-04 16:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.16 | 1-year : | 35.23 |
| Resists | First : | 25.82 | Second : | 30.16 |
| Pivot price | 25.51  |
|||
| Supports | First : | 25.28 | Second : | 24.94 |
| MAs | MA(5) : | 25.53 |
MA(20) : | 25.48 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.3 |
D(3) : | 55.2 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 25.82 | Low : | 24.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITOL ] has closed below upper band by 34.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 25.54 - 25.68 | 25.68 - 25.81 |
| Low: | 25.11 - 25.3 | 25.3 - 25.48 |
| Close: | 25.22 - 25.5 | 25.5 - 25.75 |
Fri, 31 Oct 2025
Is ITOL stock undervalued historically - 2025 Retail Activity & Reliable Volume Spike Trade Alerts - newser.com
Fri, 31 Oct 2025
Is ITOL stock undervalued historically - Layoff News & Real-Time Volume Surge Alerts - newser.com
Thu, 30 Oct 2025
Is ITOL stock undervalued historically - 2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
Wed, 29 Oct 2025
NLS Pharma (NASDAQ: NLSP): BIRD support continues for ITOL‑102 at NewCelX post‑merger - Stock Titan
Wed, 29 Oct 2025
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger - PR Newswire
Wed, 29 Oct 2025
NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|